Cancer drug dasatinib takes aim at hidden HIV in small trial

NCT ID NCT07342491

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This study tests whether dasatinib, a drug used for leukemia, can reduce the hidden HIV reservoir in people whose virus is already suppressed by antiretroviral therapy (ART). Fourteen adults on ART for at least 4 years will be randomly assigned to take dasatinib or a placebo daily for 12 weeks, with 24 weeks of follow-up. The goal is to see if the drug safely lowers the amount of dormant HIV in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dasatinib (a cancer drug taken as a pill)
What this could lead to: If it works, this could point toward a way to shrink the hidden HIV reservoir, potentially helping people manage HIV without needing lifelong medication.
What could go wrong: This is a very early, small Phase 1 trial with only 14 people. Dasatinib may not reduce the reservoir at all, and it can cause side effects like low blood counts or fluid retention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

1401, University of Washington Positive Research CRS
RECRUITING

Seattle, Washington, 98104, United States
2501, Case CRS
RECRUITING

Cleveland, Ohio, 44106, United States
Northwestern University CRS (Site # 2701)
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.